Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01331694 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01331694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01331694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
July 31, 2009
Completion date
May 31, 2010
Enrollment
76,130 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive